Hépato-Gastro & Oncologie Digestive


Targeted therapies and chemotherapy-related colitis: diagnosis and management of different entities Volume 22, issue 6, Juin 2015

1 Hôpital Cochin,
service de gastro-entérologie,
27 rue du Faubourg Saint Jacques,
75014 Paris, France
2 Institut Curie,
département d’oncologie génétique,
26 rue d’Ulm,
75005 Paris, France
* Tirés à part

Systemic anticancer drugs (cytotoxic compounds and targeted therapies) frequently induce gastrointestinal adverse effects (nausea, vomiting, diarrhea), treated by symptomatic measures. These symptoms can also reveal the occurrence of colitis, a less frequent but more severe complication which requires an early diagnosis, and an optimal and multidisciplinary management. Several entities are distinguished: Clostridium Difficile infectious colitis, neutropenic colitis, or ischemic colitis. Targeted therapies may also damage digestive mucosal, leading to colitis. Ipilimumab-related colitis is the most described, but others agents can be implied. Characteristics of these different entities will be developed in this review.